JP7826317B2 - トレプロスチニルプロドラッグで疾患を治療する方法 - Google Patents

トレプロスチニルプロドラッグで疾患を治療する方法

Info

Publication number
JP7826317B2
JP7826317B2 JP2023535715A JP2023535715A JP7826317B2 JP 7826317 B2 JP7826317 B2 JP 7826317B2 JP 2023535715 A JP2023535715 A JP 2023535715A JP 2023535715 A JP2023535715 A JP 2023535715A JP 7826317 B2 JP7826317 B2 JP 7826317B2
Authority
JP
Japan
Prior art keywords
substituted
group
prodrug
treprostinil
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023535715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553989A (ja
JP2023553989A5 (enExample
Inventor
ロバート ファレス，ケネス
バトラ，ヒテシュ
グオ，リアン
Original Assignee
ユナイテッド セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレイション filed Critical ユナイテッド セラピューティクス コーポレイション
Publication of JP2023553989A publication Critical patent/JP2023553989A/ja
Publication of JP2023553989A5 publication Critical patent/JP2023553989A5/ja
Priority to JP2026028450A priority Critical patent/JP2026102630A/ja
Application granted granted Critical
Publication of JP7826317B2 publication Critical patent/JP7826317B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023535715A 2020-12-14 2021-12-13 トレプロスチニルプロドラッグで疾患を治療する方法 Active JP7826317B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026028450A JP2026102630A (ja) 2020-12-14 2026-02-25 トレプロスチニルプロドラッグで疾患を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125145P 2020-12-14 2020-12-14
US63/125,145 2020-12-14
PCT/US2021/063133 WO2022132655A1 (en) 2020-12-14 2021-12-13 Methods of treating disease with treprostinil prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026028450A Division JP2026102630A (ja) 2020-12-14 2026-02-25 トレプロスチニルプロドラッグで疾患を治療する方法

Publications (3)

Publication Number Publication Date
JP2023553989A JP2023553989A (ja) 2023-12-26
JP2023553989A5 JP2023553989A5 (enExample) 2024-12-18
JP7826317B2 true JP7826317B2 (ja) 2026-03-09

Family

ID=79425461

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023535715A Active JP7826317B2 (ja) 2020-12-14 2021-12-13 トレプロスチニルプロドラッグで疾患を治療する方法
JP2026028450A Pending JP2026102630A (ja) 2020-12-14 2026-02-25 トレプロスチニルプロドラッグで疾患を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026028450A Pending JP2026102630A (ja) 2020-12-14 2026-02-25 トレプロスチニルプロドラッグで疾患を治療する方法

Country Status (9)

Country Link
US (3) US11826328B2 (enExample)
EP (1) EP4259121A1 (enExample)
JP (2) JP7826317B2 (enExample)
KR (2) KR102849520B1 (enExample)
CN (1) CN117062605A (enExample)
AU (1) AU2021401921A1 (enExample)
CA (1) CA3202061A1 (enExample)
IL (1) IL303668A (enExample)
WO (1) WO2022132655A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102849520B1 (ko) * 2020-12-14 2025-08-25 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
CN121241041A (zh) 2023-01-19 2025-12-30 联合治疗公司 曲前列尼尔类似物及相关制备和使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501281A (ja) 2003-05-22 2007-01-25 ユナイテッド セラピューティクス コーポレイション プロスタサイクリン類似体の送達のための化合物及び方法
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2485614A (en) 1946-08-29 1949-10-25 Chicago Bridge & Iron Co Stabilizing and guide apparatus for lifter roofs
US3037116A (en) 1957-07-26 1962-05-29 Weber Georges Apparatus for irradiating liquids
US3035516A (en) 1958-08-18 1962-05-22 Lee Brothers Company Stencil device
US3646509A (en) 1969-08-08 1972-02-29 Texas Instruments Inc Method for field stacking seismic data and system using write after read bulk data storage
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4547016A (en) 1984-08-13 1985-10-15 Eeco Incorporated Quick release mounting
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
IT1231076B (it) 1989-09-28 1991-11-12 Pirelli Cavi Spa Procedimento per la realizzazione di gruppo di connessione separabile per fibre ottiche riunite a nastro e gruppo di connessione con esso realizzato.
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
ES2214753T3 (es) 1997-11-14 2004-09-16 United Therapeutics Corporation Uso de 9-desoxi-2',9-alfa-metano-3-oxa-4,5,6-trinor-3,7-(1',3'-interfenilen)-13,14-dihidro-prostaglandina f1 para tratar la enfermedad vascular periferica.
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
KR20020012169A (ko) 1999-03-31 2002-02-15 유나이티드 쎄러퓨틱스 코포레이션 프로스타글란딘 화합물, 조성물 및 말초혈관질병 및폐고혈압증의 치료방법
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US6756117B1 (en) 2002-12-20 2004-06-29 The United States Of America As Represented By The United States Department Of Energy Photonic polymer-blend structures and method for making
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
CN1917866B (zh) 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
US7199157B2 (en) 2003-12-16 2007-04-03 United Therapeutics Corporation Use of treprostinil to improve kidney functions
DE602005020269D1 (de) 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
CA2654492C (en) 2006-05-15 2017-06-27 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
CA2678258A1 (en) 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
CN103181893A (zh) 2007-09-07 2013-07-03 联合治疗公司 针对革兰氏阴性细菌具有选择性杀菌活性的缓冲液及其使用方法
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
JP6219016B2 (ja) 2008-05-08 2017-10-25 ユナイテッド セラピューティクス コーポレーション トレプロスチニル一水和物
CN102421288B (zh) 2009-05-07 2015-04-22 联合治疗公司 前列环素类似物的固体剂型
AU2010280684B2 (en) 2009-08-07 2016-07-28 Scipharm Sarl Composition for the treatment of cystic fibrosis
KR20160132501A (ko) 2010-03-15 2016-11-18 유나이티드 세러퓨틱스 코오포레이션 폐고혈압의 치료
CN103261142B (zh) 2010-06-03 2014-12-10 联合治疗公司 曲前列环素的制备
US20120010159A1 (en) * 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
CA2710725C (en) 2010-07-22 2017-08-01 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
CA2710726C (en) 2010-07-22 2016-02-23 Alphora Research Inc. Synthesis of treprostinil and intermediates useful therein
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
ES2581762T3 (es) 2011-03-02 2016-09-07 United Therapeutics Corporation Síntesis de producto intermedio para la producción de treprostinil
US9388154B2 (en) 2011-09-12 2016-07-12 Lund Biotechnology PBC Process for preparing synthetic prostacyclins
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
SI2674413T1 (sl) 2012-06-15 2017-10-30 Scipharm Sarl Postopek za pripravo treprostinila in derivatov le-tega
WO2014085813A1 (en) 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
CN104837806A (zh) 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
US9505737B2 (en) * 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
EP2970081A4 (en) 2013-03-15 2016-10-12 United Therapeutics Corp SALTS OF TREPROSTINIL
CA2911172C (en) 2013-04-30 2021-10-19 United Therapeutics Corporation Controlled release pharmaceutical formulations
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
WO2015174197A1 (ja) 2014-05-14 2015-11-19 富士電機株式会社 半導体装置および半導体装置の製造方法
ES2908142T3 (es) 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
US20160045470A1 (en) 2014-08-12 2016-02-18 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of treprostinil diethanolamine
WO2016038532A1 (en) 2014-09-09 2016-03-17 Mylan Laboratories Limited Amorphous treprostinil diethanolamine
HU231184B1 (hu) 2014-10-08 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Treprostinil-nátrium-monohidrát és eljárás ennek előállítására
CN107108427A (zh) 2014-10-20 2017-08-29 联合治疗学有限公司 用于制备前列环素衍生物的中间体的合成
US10343979B2 (en) * 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (zh) 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
WO2016105538A1 (en) 2014-12-23 2016-06-30 Sandia Corporation Sandia National Laboratories Adjusting the ph of a pretreatment solution using carbon dioxide useful for integrating saccharification and fermentation
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2018058124A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
KR102849520B1 (ko) * 2020-12-14 2025-08-25 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501281A (ja) 2003-05-22 2007-01-25 ユナイテッド セラピューティクス コーポレイション プロスタサイクリン類似体の送達のための化合物及び方法
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Therapeutics and Clinical Risk Management，2015年，Vol.11，p.1731-1741

Also Published As

Publication number Publication date
IL303668A (en) 2023-08-01
EP4259121A1 (en) 2023-10-18
US20240130989A1 (en) 2024-04-25
KR20230134480A (ko) 2023-09-21
JP2023553989A (ja) 2023-12-26
US20260069557A1 (en) 2026-03-12
CN117062605A (zh) 2023-11-14
WO2022132655A1 (en) 2022-06-23
JP2026102630A (ja) 2026-06-23
US12491170B2 (en) 2025-12-09
AU2021401921A1 (en) 2023-07-06
KR20250133451A (ko) 2025-09-05
US20220323387A1 (en) 2022-10-13
US11826328B2 (en) 2023-11-28
KR102849520B1 (ko) 2025-08-25
CA3202061A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
JP2026016361A (ja) トレプロスチニルプロドラッグ
CA1177398A (en) Watersoluble derivatives of non-steroidal anti- inflammatory agents and a process for the production thereof
RU2523543C2 (ru) Соли производных тетерагидро-имидазо[1,5-a]пиразина, способы их получения и их медицинское применение
US20260069557A1 (en) Stable treprostinil prodrugs
JP2002517459A (ja) β２−アドレナリン作動性レセプターアゴニスト
JP2022188082A (ja) トレプロスチニルプロドラッグ
US20210284621A1 (en) Cannabinoids and uses thereof
KR20240012354A (ko) (e)-3,6-비스[4-(n-카보닐-2-프로페닐)아미도부틸]-2,5-디케토피페라진(fdkp)을 추가로 포함하는, 트레프로스티닐 및 이의 프로드러그의 건조 분말 조성물
EP2473480B1 (en) Novel antibacterial hydroxyphenyl compound
JPS61501774A (ja) 短時間作用性β−アドレナリン作用遮断剤の安定な医薬組成物
US20240247252A1 (en) Novel compounds for the development of reversible covalent drugs
TW202502721A (zh) 一種曲前列環素衍生物、其製備方法及應用
JP2002517461A (ja) ブラジキニンアンタゴニスト
US20250074871A1 (en) Phenethylamines and methods of preparation thereof
EP2199274A1 (en) Co-crystals of tramadol and paracetamol
US20220218641A1 (en) Methods of treatment with deuterated analogs of d-serine
WO2024131672A1 (zh) 二苯基吡嗪类衍生物、其制备方法及应用
HK40096678A (en) Pharmaceutical composition for preventing or treating fibrosis
BR122025003385A2 (pt) Formulações farmacêuticas líquidas de conjugados de pth, seus métodos de fabricação e usos
HK1173136B (en) Novel antibacterial hydroxyphenyl compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260225

R150 Certificate of patent or registration of utility model

Ref document number: 7826317

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150